Facial psoriasis linked to reduced QoL, but ixekizumab helps

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Facial psoriasis is associated with reduced health-related QoL (HRQoL), while ixekizumab (IXE) treatment is associated with facial clearance.

Why this matters

  • Combined results of UNCOVER-2 and UNCOVER-3 trials suggest the efficacy of ixekizumab for facial psoriasis, whi...